Objective: Imaging of regional cerebral glucose metabolism with PET and striatal dopamine D2/D3 receptors (D2R) with SPECT improves the differential diagnosis of parkinsonism. We prospectively investigated 1) the diagnostic merits of these approaches in differentiating between Lewy body diseases (LBD; majority Parkinson disease [PD]) and atypical parkinsonian syndromes (APS); 2) the diagnostic value of [¹⁸F]fluorodeoxyglucose (FDG)-PET to differentiate among APS subgroups.
Methods: Ninety-five of 107 consecutive patients with clinically suspected APS referred for imaging were recruited. [¹⁸F]FDG-PET scans were analyzed by visual assessment (including individual voxel-based statistical maps). Based on a priori defined disease-specific patterns, patients with putative APS were differentiated from LBD (first level) and allocated to the subgroups multiple system atrophy (MSA), progressive supranuclear palsy (PSP), or corticobasal degeneration (CBD) (second level). [¹²³I] iodobenzamide (IBZM)-SPECT datasets were subjected to an observer-independent regions-of-interest analysis to assess striatal D2R availability. Movement disorder specialists made final clinical diagnoses after a median follow-up time of 12 months.
Results: Seventy-eight patients with clinically verified APS (n = 44) or LBD (n = 34) were included in the statistical analysis. The area under the receiver operating characteristic curve for discrimination between APS and LBD was significantly larger for [¹⁸F]FDG-PET (0.94) than for [¹²³I]IBZM-SPECT (0.74; p = 0.0006). Sensitivity/specificity of [¹⁸F]FDG-PET for diagnosing APS was 86%/91%, respectively. Sensitivity/specificity of [¹⁸F]FDG-PET in identifying APS subgroups was 77%/97% for MSA, 74%/95% for PSP, and 75%/92% for CBD.
Conclusions: The diagnostic accuracy of [¹⁸F]FDG-PET for discriminating LBD from APS is considerably higher than for [¹²³I]IBZM-SPECT. [¹⁸F]FDG-PET reliably differentiates APS subgroups.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1212/WNL.0b013e31826c1b0a | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Therapeutic potential and pharmacological mechanisms of Traditional Chinese Medicine in gout treatment.
Acta Pharmacol Sin
January 2025
Innovation Research Institute of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Gout is a systemic metabolic disorder caused by elevated uric acid (UA) levels, affecting over 1% of the population. The most common complication of gout is gouty arthritis (GA), characterized by swelling, pain or tenderness in peripheral joints or bursae, which can lead to the formation of tophi. At present, western medicines like colchicine, febuxostat and allopurinol are the primary treatment strategy to alleviate pain and prevent flare-ups in patients with GA, but they have significant side effects and increased mortality risks.
View Article and Find Full Text PDFRole of transforming growth factor-β1 in regulating adipocyte progenitors.
Sci Rep
January 2025
Research Center for Pre-Disease Science, Faculty of Education and Research Promotion, University of Toyama, Toyama, 930-0194, Japan.
Adipose tissue (AT) metabolism involves coordinating various cells and cellular processes to regulate energy storage, release, and overall metabolic homeostasis. Therein, macrophage and its cytokine are important in controlling tissue homeostasis. Among cytokines, the role of transforming growth factor-β1 (Tgf-β1), a cytokine abundantly expressed in CD206 M2-like macrophage and correlated with the expansion of AT and fibrosis, in AT metabolism, remains unknown.
View Article and Find Full Text PDFAstragalus polysaccharide mediates lnc-GD2H to regulate proliferation and differentiation of C2C12 muscle cells under hypoxic condition.
Tissue Cell
January 2025
Guangdong Traditional Medical and Sports Injury Rehabilitation Research Institute, The Affiliated Guangdong Second Provincial General Hospital of Jinan University, Guangzhou, Guangdong, China. Electronic address:
Astragalus polysaccharide (APS) is a bioactive component of Astragalus species that shows protective effects on C2C12 muscle cell proliferation and differentiation under hypoxic conditions. In this study, EdU staining, cell scratch testing, quantitative reverse-transcription polymerase chain reaction, Western blotting, immunofluorescence analysis, and lnc-GD2H silencing were used to investigated the protective effects and mechanisms of action of APS against CoCl-induced hypoxic injury of muscle cells. Our results showed that APS promoted cell proliferation and increased the expression of lnc-GD2H, c-Myc, and Ki-67.
View Article and Find Full Text PDFAction potential-independent spontaneous microdomain Ca transients-mediated continuous neurotransmission regulates hyperalgesia.
Proc Natl Acad Sci U S A
January 2025
Department of Neurology, the Second Affiliated Hospital, Neuroscience Research Center, Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an 710000, China.
Neurotransmitters and neuromodulators can be released via either action potential (AP)-evoked transient or AP-independent continuous neurotransmission. The elevated AP-evoked neurotransmission in the primary sensory neurons plays crucial roles in hyperalgesia. However, whether and how the AP-independent continuous neurotransmission contributes to hyperalgesia remains largely unknown.
View Article and Find Full Text PDFEffects of Astragalus polysaccharide on the structure and function of skeletal muscle in D-galactose-induced C57BL/6J mice.
Am J Transl Res
December 2024
Department of Geriatrics, The First Affiliated Hospital of Chongqing Medical University Chongqing 400042, China.
Objective: To investigate the effects of Astragalus polysaccharide (APS) on skeletal muscle structure and function in D-galactose (D-gal)-induced C57BL/6J mice.
Methods: Eighteen male C57BL/6J mice of specific pathogen-free (SPF) grade, aged 8 weeks, were selected and divided into three groups: a control group (0.9% saline gavage for 16 weeks), a D-gal group (subcutaneous injection of 200 mg/kg D-galactose in the upper neck region, once daily for 8 weeks), and a D-gal + APS group (subcutaneous injection of 200 mg/kg D-galactose, once daily for 8 weeks, with concurrent administration of 100 mg/kg APS by gavage for 8 weeks).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!